Get started
Author

Chisa Wada

Observed names: C. Wada, Wada, Chisa
OpenAlex ID: A5019542578
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies
2015 · Shigeo Kamitsuji, Takashi Matsuda, et al. · Journal of Human Genetics · 27
Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models
2023 · Genzui Setsu, Megumi Goto, et al. · European Journal of Pharmacology · 26
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma
2018 · Makoto Nakagawa, Shuhei Fujita, et al. · Cancer Science · 25
PDF
Deep learning generates custom-made logistic regression models for explaining how breast cancer subtypes are classified
2023 · Takuma Shibahara, Chisa Wada, et al. · PLoS ONE · 12
PDF
Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways
2019 · Yasuhiro Hama, Toshihiro Banjo, et al. · Blood · 4
Pf225 Azacitidine (aza) Enhances Antileukemic Activity of the Mdm2 Inhibitor Milademetan in Tp53 Wild-type Acute Myeloid Leukemia (aml)
2019 · S. Noguchi, T. Seki, et al. · HemaSphere · 4
EZH1/2 Dual Inhibitor Valemetostat Tosylate (DS-3201b) Acts Differently from EZH2 Selective Inhibitor on Epigenetic Landscape to Exert Greater Anti-Tumor Effect Against Diffuse Large B-Cell Lymphoma
2021 · Toshihiro Banjo, Yasuhiro Hama, et al. · Blood · 2
Novel Stem Cell-Targeted Therapy for Multiple Myeloma Based on Dual Inhibition of EZH1/2
2017 · Makoto Nakagawa, Shuhei Fujita, et al. · Blood · 2
Abstract 3790: Preclinical assessment of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with trastuzumab deruxtecan and datopotamab deruxtecan for multiple solid tumors
2025 · Daisuke Honma, Akiko Toyota, et al. · Cancer Research · 1
Deep Learning Generates Custom-made Logistic Regression Models for Explaining how Breast Cancer Subtypes are Classified
2021 · Takuma Shibahara, Chisa Wada, et al. · Research Square · 1
PDF
Deep learning generates custom-made logistic regression models for explaining how breast cancer subtypes are classified
2021 · Takuma Shibahara, Chisa Wada, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
P3.02-042 DS-1205b, a Novel, Selective, Inhibitor of AXL, Delays the Onset of Resistance and Overcomes Acquired Resistance to EGFR-TKIs
2017 · T. Jimbo, T. Taira, et al. · Journal of Thoracic Oncology · 1
PDF
DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR-TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model
2017 · T. Jimbo, T. Taira, et al. · Annals of Oncology · 1
Abstract 5303: Temporal dynamics of transcriptional and spatial landscape in tumor microenvironment of esophageal squamous cell carcinoma during chemotherapy treatment
2025 · Hiroki Yamashita, Chiaki Mashima, et al. · Cancer Research
Deep learning generates custom-made logistic regression models for explaining how breast cancer subtypes are classified
2021 · Shibahara, Takuma, Wada, Chisa, et al. · Figshare
Works count: 15
Citation count: 107
H-index: 4
I10-index: 4
Year
Topic
Type